Prospective comparative study between two first-line regimens for Helicobacter pylori eradication: Non-bismuth quadruple versus bismuth quadruple therapy.

Background: The Maastricht V Consensus recommends quadruple therapies as first-line Helicobacter pylori treatment in high clarithromycin (CLA) resistance areas.

Aims: To compare efficacy, side effects and compliance between quadruple concomitant non-bismuth vs bismuth quadruple therapy.

Method: Prospective study enrolling H.